Literature DB >> 15589062

Hypoglycemia in type 2 diabetes: a critical review.

Glen H Murata1, William C Duckworth, Richard M Hoffman, Christopher S Wendel, M Jane Mohler, Jayendra H Shah.   

Abstract

Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be identified. Because symptoms are an unreliable way of establishing the diagnosis, SMBG should be considered for the patients at highest risk, particularly as they approach their glycemic targets. SMBG is superior to HbA1c in forecasting the hypoglycemia rate because it provides information about glucose variability--an independent risk factor. Patient education and medication changes are potential ways of reducing the hypoglycemia rate. However, it remains to be proven that patient education is beneficial in this regard.

Entities:  

Mesh:

Year:  2004        PMID: 15589062     DOI: 10.1016/j.biopha.2004.09.001

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

Review 1.  [New differential therapy of type 2 diabetes].

Authors:  M Schütt; H H Klein
Journal:  Internist (Berl)       Date:  2011-04       Impact factor: 0.743

Review 2.  The treatment of type 2 diabetes.

Authors:  Andreas F H Pfeiffer; Harald H Klein
Journal:  Dtsch Arztebl Int       Date:  2014-01-31       Impact factor: 5.594

3.  The impact of the angiotensin-converting enzyme insertion/deletion polymorphism on severe hypoglycemia in Type 2 diabetes.

Authors:  Rachel M Freathy; Kathryn F Lonnen; Anna M Steele; Jayne A L Minton; Timothy M Frayling; Andrew T Hattersley; Kenneth M Macleod
Journal:  Rev Diabet Stud       Date:  2006-08-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.